Cristina Wilbur - Roche Holding Executive
| RHHVF Stock | USD 346.25 2.23 0.64% |
Executive
Ms. Cristina A. Wilbur was Member of the Corporationrationrate Executive Committee, Head Group Human Resources of Roche Holding Ltd since March 2016. She holds BS degree in Accounting from California Polytechnic University. She served at EGG as Human Resources and Payroll Manager and later as Human Resources Director. In 2001 she joined PerkinElmer Optoelectronics as Human Resources Director. In 2002 she joined Roche Diagnostics Corporation as Human Resources Director, where in 2006 she was appointed VicePresident, North America Region Human Resources and Communications. In 2010 she became Senior VicePresident and Global Head of Human Resources at Roche Diagnostics Division. She was Chair of the Board of Directors at International School Basel Reinach AG. since 2016.
| Age | 56 |
| Tenure | 9 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suresh Khemani | Scilex Holding | 65 | |
| William Winters | Novartis AG ADR | 60 | |
| Lluis Gomez | Grifols SA ADR | 42 | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Ruth March | AstraZeneca PLC ADR | N/A | |
| Roy Papatheodorou | Sanofi ADR | 47 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Klaus Moosmayer | Novartis AG ADR | 57 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Kenji Yasukawa | Astellas Pharma | 63 | |
| Susan MD | AstraZeneca PLC ADR | 59 | |
| John Tsai | Novartis AG ADR | 54 | |
| Pr Belvisi | AstraZeneca PLC ADR | N/A | |
| Harry Kirsch | Novartis AG | 58 | |
| Vicente Torre | Grifols SA ADR | 64 | |
| Jeffrey Pott | AstraZeneca PLC | N/A | |
| Steffen Lang | Novartis AG | 56 | |
| Steven Baert | Novartis AG ADR | 45 | |
| Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Claudia Bockstiegel, G Counsel | ||
| Bruno Eschli, Head Relations | ||
| Johannes MD, Head Devel | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Alan Hippe, CFO and IT Officer | ||
| Severin Schwan, CEO and Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 287.91 B | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 18.04 X | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 3.97 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Roche OTC Stock
Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.